2023 | Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis | Liam, Chong Kin; Ahmad, Azura Rozila; Hsia, Te-Chun; Zhou, Jianying; Kim, Dong-Wan; Soo, Ross Andrew; Cheng, Ying; Lu, Shun; Shin, Sang Won; CHIH-HSIN YANG ; Zhang, Yiping; Zhao, Jun; Berghoff, Karin; Bruns, Rolf; Johne, Andreas; Wu, Yi-Long | Clinical cancer research : an official journal of the American Association for Cancer Research | 8 | 4 | |
2023 | Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial | Mazieres, Julien; Paik, Paul K; Garassino, Marina C; Le, Xiuning; Sakai, Hiroshi; Veillon, Remi; Smit, Egbert F; Cortot, Alexis B; Raskin, Jo; Viteri, Santiago; Wu, Yi-Long; CHIH-HSIN YANG ; Ahn, Myung-Ju; Ma, Rui; Zhao, Jun; O'Brate, Aurora; Berghoff, Karin; Bruns, Rolf; Otto, Gordon; Johne, Andreas; Felip, Enriqueta; Thomas, Michael | JAMA oncology | 12 | 4 | |